Reviewing broker data, just retail selling through ANZ and Commsec.
I spoke with management, the way I see it is the following;
the longer the co doesn’t release an announcement, the better. Management have informed me that one primary endpoint of the study is safety, and if one patient experiences an adverse reaction, they will report it to the ASX to maintain “continuous disclosure.”
That should tell you all you need to know
Interesting, page-5432
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
